Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Renal Toxicities Associated With Pembrolizumab

H. Izzedine, A. Mathian, S. Champiat, C. Picard, C. Mateus, E. Routier, A. Varga, D. Malka, A. Leary, J. Michels, J. Michot, A. Marabelle, O. Lambotte, Z. Amoura, J. Soria, Sihem Kaaki, N. Quellard, J. Goujon, I. Brochériou
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract Objective Expanded clinical experience with patients treated by pembrolizumab has accumulated. However, renal toxicities associated with this anti-programmed cell death 1 agent are poorly described because kidney histology is rarely sought. As a nephrology referral centre, we aimed to describe the clinic-biological and histopathological characteristics of pembrolizumab-related nephropathy and its response to treatment. Methods We conducted a monocentric large case series study, including all pembrolizumab-treated cancer patients presenting a renal toxicity addressed to our centre from 2015 to 2017. Results A total of 12 patients (7 men) out of 676 pembrolizumab-treated patients (incidence 1.77%) were included (median age 69.75 years). Patients were referred for acute kidney injury (n = 10) and/or proteinuria (n = 2). A kidney biopsy was performed in all patients, with a median duration of use of 9 months (range 1–24 months) after the beginning of treatment. Biopsy showed that four patients had acute interstitial nephritis (AIN), whereas five had acute tubular injury (ATI) alone, one had minimal change disease (MCD) and ATI, and one had MCD alone. Pembrolizumab withdrawal coupled with corticosteroid therapy was the most effective treatment for kidney function recovery. Drug reintroduction resulted in a more severe recurrence of AIN in one patient who required maintenance of pembrolizumab. Two patients died of cancer progression with one of them developing severe renal failure requiring dialysis. Conclusion In our series, ATI, AIN and MCD are the most frequent forms of kidney involvement under pembrolizumab therapy. Kidney dysfunction is usually isolated but can be severe. Use of corticosteroids in case of AIN improves the glomerular filtration rate.
This paper references
10.1007/s00262-011-1193-1
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
D. McNeel (2011)
10.1159/000013365
Recovery of Minimal Change Nephrotic Syndrome and Acute Renal Failure in a Patient withRenal Cell Carcinoma
T. Auguet (1998)
10.1053/j.ajkd.2016.02.057
Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.
A. Shirali (2016)
10.1056/NEJMc1801663
Adverse Events Associated with Immune Checkpoint Blockade.
K. Jhaveri (2018)
10.1097/CJI.0000000000000189
Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report
Robin A Daanen (2017)
10.1093/rheumatology/kew050
Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2.
N. Keer (2016)
10.1016/j.clim.2008.03.506
Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis.
M. Slot (2008)
10.1056/NEJMOA1611299
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
A. Eggermont (2016)
10.1016/0002-9343(86)90049-5
Glomerular lesions in lymphomas and leukemias.
D. Dabbs (1986)
Induction of B7-1in podocytes is associated with nephrotic syndrome
J Reiser (2004)
10.1016/j.kint.2016.04.008
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
F. Cortazar (2016)
10.1097/MD.0000000000000207
Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF)
H. Izzedine (2014)
10.1007/s10637-014-0092-7
Kidney injuries related to ipilimumab
H. Izzedine (2014)
10.1681/ASN.2015030266
B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy.
E. Gagliardini (2016)
Immune-related adverse events (irAEs) following CTLA-4 and PD-1/PD-L1 blockade in Kidney disease associated with pembrolizumab | 87 advanced melanoma: a comprehensive rapid autopsy study
P Bavi (2016)
10.1200/JCO.2014.58.1041
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
D. McDermott (2015)
10.1007/s10637-015-0243-5
Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer
H. Horinouchi (2015)
10.1002/art.38282
Drug‐Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA‐4
B. Goldstein (2014)
10.1056/NEJMc1400502
Abatacept in B7-1-positive proteinuric kidney disease.
N. Alachkar (2014)
10.1056/NEJMc0904283
Anti-CTLA4 antibody-induced lupus nephritis.
F. Fadel (2009)
A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome.
G. Lagrue (1975)
A case of IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma
S Kishi (2018)
10.1093/annonc/mdu205
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
M. Aglietta (2014)
Pembrolizumabassociated minimal change disease in a patient with malignant pleural mesothelioma
A Bickel (2016)
10.1053/j.ajkd.2017.04.026
Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases.
A. Kitchlu (2017)
10.1016/J.YONC.2012.07.009
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
A. Tsao (2012)
10.1186/s12882-016-0408-2
Nivolumab-associated acute glomerulonephritis: a case report and literature review
Kyungsuk Jung (2016)
10.1007/s12032-010-9606-0
Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
K. Harmankaya (2011)
10.1097/PAP.0000000000000122
Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies
M. Troxell (2016)
10.1016/S1470-2045(14)70189-5
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
E. Kwon (2014)
10.1681/ASN.2011050464
The pathophysiology of IgA nephropathy.
H. Suzuki (2011)
10.1016/j.kint.2015.11.028
Ipilimumab-associated minimal-change disease.
Jason M. Kidd (2016)
10.1002/cncr.30642
Immune checkpoint inhibitors in challenging populations
D. Johnson (2017)
10.1093/rheumatology/kes034
Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis.
B. Wilde (2012)
10.1159/000455014
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
R. Wanchoo (2017)
10.1016/j.kint.2016.05.024
Checkmate: kidney injury associated with targeted cancer immunotherapy.
M. Perazella (2016)
10.1016/S1470-2045(12)70090-6
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
K. Margolin (2012)
10.2169/internalmedicine.9814-17
IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma
S. Kishi (2018)
10.1056/NEJMoa1304572
Abatacept in B7-1-positive proteinuric kidney disease.
Chih-Chuan Yu (2013)
B 7 - 1 is not induced in podocytes of human and experimental diabetic nephropa
E Gagliardini (2016)
10.1093/NDT/GFG1060
Secondary minimal change disease.
R. Glassock (2003)
10.1093/ndt/gfw382
Renal effects of immune checkpoint inhibitors
H. Izzedine (2017)
10.2215/CJN.03800609
Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.
E. T. Mccarthy (2010)
10.1159/000168592
Minimal-change glomerulopathy and carcinoma. Report of two cases and review of the literature.
A. Martínez-Vea (1993)
10.1186/s12885-016-2718-y
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
A. Bickel (2016)
10.1093/ckj/sfw024
Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
N. Murakami (2016)
10.1016/j.ctrv.2016.02.003
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.
T. Eigentler (2016)
10.1016/S1074-7613(00)80089-8
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H. Nishimura (1999)
10.1172/JCI20402
Induction of B7-1 in podocytes is associated with nephrotic syndrome.
J. Reiser (2004)
10.1200/JCO.2012.47.5095
Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab.
D. Minor (2013)
10.1038/KI.1986.209
Neoplasia and glomerular injury.
C. Alpers (1986)
10.1093/rheumatology/kew063
Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.
Rob R H van den Brom (2016)
10.2147/DDDT.S146286
Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials
Manni Wang (2017)
10.1056/NEJMoa1305133
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)



This paper is referenced by
10.1093/ckj/sfy114
Pembrolizumab-related renal toxicities: diagnosis first, treatment later
B. Sprangers (2019)
10.1177/2399369319866837
Cancer immunotherapy and its renal effects
Omar Mamlouk (2019)
10.34067/kid.0000852019
Immune checkpoint inhibitor nephrotoxicity: Update 2020
Shruti Gupta (2020)
10.1177/2399369319841616
Evolution of the kidney–cancer connection
M. Perazella (2019)
10.1016/J.NEFRO.2019.11.007
Pembrolizumab in hemodialysis patients. Is it safe
Melisa Guzmán Vasquez (2020)
10.1016/j.nephro.2019.05.006
Toxicités rénales des inhibiteurs des points de contrôle de l’auto-immunité
H. Izzedine (2020)
10.1016/j.revmed.2019.09.005
Toxicités immunologiques induites par les inhibiteurs de checkpoint en 2019 : mise au point
Thibault Comont (2020)
10.1016/j.nephro.2019.06.003
Toxicités rénales des thérapies ciblées en oncologie
H. Izzedine (2020)
10.1007/s00520-020-05710-8
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors
M. Suarez-Almazor (2020)
10.1016/J.KINT.2019.07.022
Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
M. Perazella (2019)
10.1093/ckj/sfaa027
Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?
Juliana Draibe (2020)
10.34067/KID.0001192019
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor–Associated Acute Kidney Injury: PRO
M. Eijgelsheim (2020)
10.1016/j.jaip.2020.06.028
Balancing Cancer Immunotherapy Efficacy and Toxicity
D. Johnson (2020)
10.1056/NEJMc1801663
Adverse Events Associated with Immune Checkpoint Blockade.
K. Jhaveri (2018)
10.1177/1078155220961553
Interstitial nephritis with pembrolizumab: A case report and review
A. Bejarano (2020)
10.1016/j.ekir.2020.08.002
Hyperacute Onset of Immune Checkpoint Inhibitor–Related Acute Interstitial Nephritis
Ibrahim Tawhari (2020)
10.2215/CJN.02340219
AKI in Patients Receiving Immune Checkpoint Inhibitors.
M. Perazella (2019)
10.1016/j.semnephrol.2019.12.006
Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma.
E. Jaimes (2020)
10.1038/s41598-020-80853-6
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity
M. Arita (2021)
10.1080/17512433.2019.1613888
The nephrotoxicity of new immunotherapies
K. Sury (2019)
10.1093/ckj/sfaa008
Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience
Diana Oleas (2020)
10.32932/pjnh.2020.01.047
Nephrotoxicity in patients receiving immune checkpoint inhibitors
Teresa Chuva (2020)
10.34067/kid.0000152019
Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge
S. Manohar (2020)
10.1016/j.semnephrol.2019.12.009
Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma.
Mamta Parikh (2020)
10.1111/ajco.13387
Renal immune‐related adverse events of immune checkpoint inhibitor
Rongrong Hu (2020)
10.3389/fimmu.2020.574271
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
R. Franzin (2020)
10.1007/s40620-019-00691-2
The renal adverse effects of cancer immunotherapy
Natalie C. Steinel (2020)
10.2215/CJN.00990119
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
H. Seethapathy (2019)
10.2169/internalmedicine.4260-19
Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab
Takahiro Taki (2020)
10.1016/j.ekir.2020.10.002
A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease
A. Kitchlu (2021)
10.1136/jitc-2019-000467
Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes
Alejandro Meraz-Muñoz (2020)
Effets secondaires rénaux chez les patients traités par immunothérapie par anti-PD1 pour mélanome métastatique : étude réalisée en vie réelle dans une cohorte de 239 patients
C. Stein (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar